- AHT Partner Portal
- Business Development
- Home Page New
- Privacy Policy
- Think Research | Knowledge-based tools and clinical content for clinicians
[vc_row full_width=”stretch_row” el_id=”main-banner-shift” css=”.vc_custom_1441900512935{padding-top: 40px !important;padding-bottom: 60px !important;background-color: #47b5e6 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”banner-bg”][vc_column width=”1/6″ css=”.vc_custom_1439930288923{padding-top: 40px !important;padding-bottom: 20px !important;}”][vc_column_text] [/vc_column_text][/vc_column][vc_column width=”2/3″][vc_column_text css=”.vc_custom_1441900500442{padding-top: 40px !important;padding-bottom: 40px !important;}”]
Think Research Leadership
[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_column_text] [/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”30px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”50px”][vc_single_image image=”4950″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1441813400511{padding-top: 40px !important;}”]
Sachin Aggarwal – CEO
Sachin Aggarwal is the Chief Executive Officer of Think Research. He joined the team in 2010 as Executive Vice President and Chief Operating Officer. Prior to joining Think Research, Sachin served as the Deputy Chief of Staff for the Office of the Leader of the Opposition, where he managed six departments, including the Leader’s Executive Team. Sachin has served on the Board of Directors for numerous community outreach programs, including Dixon Hall Neighbourhood Services and the People with AIDS Foundation. He was called to the Bar in Ontario and in New York after earning a law degree from the University of Toronto and holds a MBA from the Rotman School of Management. [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1440116584960{background-color: #efefef !important;}”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”4951″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440873892160{padding-top: 40px !important;}”]
Chris O’Connor – President and Founder
Dr. Chris O’Connor is the President and Founder of Think Research and a practicing critical care physician in the Intensive Care Unit at Trillium Health Partners. Chris began his medical career at Trillium Health Partners in 2000 and served as their Director of Medical Informatics. In 2006, he received the Ontario Innovation Award for Improving Quality & Patient Safety after successfully launching the first ever hospital-wide order set project. He also won the Emerging Leader in Canadian Informatics Award in 2007 for innovation in the health care field. Since founding Think Research in 2006, he has been actively involved in the company’s clinical development process. [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”60px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”20px”][vc_single_image image=”4949″ img_size=”200×200″ alignment=”center” el_class=”vertical-align”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440874961418{padding-top: 20px !important;}” el_class=”vertical-align”]
Mark Sakamoto – Executive VP
Mark is the Executive Vice President for Think Research. A lawyer by training, Mark has enjoyed a rich and varied career, having worked at a national law firm and served as a senior political advisor to a national party leader. Prior to joining our Executive Team, Mark worked as an Executive Manager for the Canadian Broadcast Corporation where he led negotiations for hundreds of content deals. He is an entrepreneur and investor in digital health and digital media and has been instrumental in driving the growth of Think Research. In 2014, he authored his first book, Forgiveness: A Gift from My Grandparents , which went on to be a #1 national best seller. [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1440116584960{background-color: #efefef !important;}”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”4946″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440873957652{padding-top: 40px !important;}”]
Joanna Carroll – Chief Talent Officer
Joanna is Think Research’s Chief Talent Officer. Over the past five years, Joanna has been instrumental in overseeing the hiring during Think Research’s rapid expansion as it has grown from a small start-up to a team of over 130 full- and part-time staff. Joanna also serves as Think Research’s Chief Privacy Officer and as a legal advisor to our Executive Team. She holds a law degree from the University of Calgary and has over 15 years experience practicing law as an employment lawyer and commercial litigator. Joanna sits on the Board of Directors for two non-profit agencies in downtown Toronto and Chairs the Human Resources Committee of one. [/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”4948″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440962239222{padding-top: 40px !important;}”]
Saurabh Mukhi – CTO
As Chief Technology Officer for Think Research, Saurabh leads a growing team of highly skilled developers and IT professionals. Saurabh has been central in developing Think Research’s collaborative software solutions with industry partners like MED-PASS, INTERACT and Health Outcomes Worldwide. Previously, Saurabh worked as a Management Consultant with KPMG within their IT strategy services practice before founding his own mobile health company. Saurabh has a Bachelor of Mathematics in Computer Science from the University of Waterloo as well as a MBA from the Rotman School of Management.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”597078″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1506952578673{padding-top: 40px !important;}”]
William Falk – Executive in Residence
Prior to joining Think Research, he was a partner with PwC and led their healthcare team in Canada. William has spent more than 25 years as a strategist and management consultant in New York and Toronto, advising top academic centres, governments, and innovative companies in healthcare. He has academic appointments as an Executive Fellow at both the University of Toronto’s Rotman School of Management and The Mowat Centre, and is a Senior Fellow at the C.D. Howe Institute.
[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1440775300138{background-color: #efefef !important;}”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”4947″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440874038280{padding-top: 40px !important;}”]
Dylan Hardy – COO
Dylan is Think Research’s Chief Operating Officer. Over the past ten years, he has worked extensively within health care on quality transformation programs, patient access improvement initiatives, and technology needs assessments and implementations. Dylan is an invited speaker on health care quality and Lean improvement topics and has trained more than 1,000 physicians, nurses and senior leaders on quality improvement. He has designed and led large-scale provincial transformation programs such as Ontario’s Emergency Department Performance Improvement Program (ED-PIP). Prior to joining Think Research, Dylan was a Partner in KPMG’s Healthcare Practice working with providers and policy makers in Canada, the US and Asia.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”20px”][vc_row_inner][vc_column_inner width=”1/3″][vc_empty_space height=”60px”][vc_single_image image=”4952″ img_size=”200×200″ alignment=”center”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1506956677728{padding-top: 40px !important;}”]
Kirsten Lewis – Clinical Director
Kirsten is the Clinical Director on Think Research’s Research and Development team and has been a registered nurse for nearly 30 years. Since joining Think Research, she has worked extensively on building our Order Set library in collaboration with leading health care associations. Prior to joining Think Research, she worked as a Clinical Manager at the University Health Network. While at Toronto General Hospital, Kirsten focused on improving patient flows, enhancing the quality of care delivered to patients and maximizing capacity. In 2012, she coordinated a province-wide roll out of the Ontario Renal Plan where she provided expert clinical consultation.[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”20px”][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1440116584960{background-color: #efefef !important;}”][vc_column][vc_empty_space height=”20px”][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row”][vc_column][vc_empty_space height=”20px”][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1440117057283{background-color: #47b5e6 !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column][vc_empty_space height=”60px”][vc_row_inner][vc_column_inner width=”1/6″] [/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text css=”.vc_custom_1440774044271{padding-bottom: 40px !important;}”]
Want to be part of the team? We’re hiring!
Join a growing team of bright, energetic people brought together by a desire to improve our healthcare systems.
[/vc_column_text][vc_btn title=”FIND YOUR FIT” style=”flat” shape=”square” color=”primary” align=”center” link=”url:http%3A%2F%2Fwww.thinkresearchgroup.com%2Fcompany%2Fcareers%2F||”][/vc_column_inner][vc_column_inner width=”1/6″] [/vc_column_inner][/vc_row_inner][vc_empty_space height=”60px”][/vc_column][/vc_row]
- Privacy Overview
- Strictly Necessary Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
Think Research Announces Appointment of Dr. Eric Hoskins, Former Ontario Health Minister, to Board of Directors
TORONTO , Jan. 18, 2021 /CNW/ - Think Research Corporation (TSXV: THNK) announced today that it has appointed former Ontario Health Minister, Dr. Eric Hoskins , to its board of directors. Dr. Hoskins is a medical doctor and public health expert with more than 30 years' experience in healthcare, public policy, economic development and international trade. Dr. Hoskins recently served as the Chair of the Federal Advisory Council on the Implementation of National Pharmacare. He previously served as president of War Child Canada and was awarded the Order of Canada in 2007 for his humanitarian work.
"We are delighted to welcome Dr. Hoskins to Think Research's board," said Sachin Aggarwal , Think Research CEO. "His proven history as a leader in both the healthcare and public policy space and his longtime support of digital health innovation in Canada makes him a great asset to our organization. I look forward to having Dr. Hoskins' expert counsel and oversight on our board as we work to achieve our common goal — ensuring that everyone has access to the best healthcare possible."
During Dr. Hoskins' nearly 10 years as a member of provincial parliament in Ontario , he held several cabinet positions including Minister of Health and Long-Term Care; Economic Development, Trade and Employment; Children and Youth Services; as well as Citizenship and Immigration. As a tireless health advocate, Dr. Hoskins has many years experience creating and delivering health programs in Africa and the Middle East .
"I am excited to join the board of Think Research — a company focused squarely on improving patient outcomes through innovation, data and technology. Think Research supports healthcare providers and health systems, empowering clinicians to apply best practices and deliver patient-focused evidence-based care," Dr. Hoskins said. "Think Research is already making a huge difference in healthcare systems here in Canada and around the world, and I am proud to be part of their team."
Dr. Hoskins joins the other experienced members of the Think Research Board of Directors namely, Kirstine Stewart , author of bestselling leadership book Our Turn and former Vice President of Media at Twitter North America; Cindy Gray , Managing Director, CEO and founder of Calgary -based consulting firm 5 Quarters Investor Relations Inc.; Barry Reiter , Chair of Bennett Jones LLP's Technology, Media & Entertainment Group; Richard Wells , Chief Financial Officer of Waterton Global Resource Management, Inc.; Abe Schwartz , president of Schwartz Technologies Corporation; and Sachin Aggarwa l, CEO of Think Research since 2010.
The Company announced it has granted an aggregate of 21,505 deferred share units (each, a "DSU") to Eric Hoskins as a non-executive director of the Company pursuant to the Incentive Plan. Each DSU represents the right to receive one Common Share upon the holder of such DSU ceasing to be employed as an officer, employee or director of the Company or any of its subsidiaries.
Dr. Hoskins' appointment is subject to the requisite clearing of his Personal Information Form in accordance with the rules of the TSX Venture Exchange.
About Think Research Corporation
Think Research is an industry leader in delivering integrated digital healthcare solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process, standardize care, and improve patient outcomes. For over a decade, Think Research's cloud-based, EMR-agnostic digital tools have empowered clinicians around the world and positively impacted millions of patients across the continuum of care – including primary physician care, acute care hospitals and surgical suites as well as community and seniors care. Think Research is proud to serve as a trusted health system partner to a rapidly growing, global client base that spans three continents and more than 2,200 healthcare facilities.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Think Research Corporation
- Featured Stocks
- Free Daily Newsletter
- See All Health Stock Lists
- Biotechnology Stocks
- Pharmaceutical Stocks
- Big Pharma Stocks
- Healthcare Stocks
- Medical Stocks
- Diagnostics & Research Stocks
- Medical Device Stocks
- Biotechnology News
- Pharmaceutical News
- Medical News
- Healthcare News
- Stock Screener
Think Research Appoints Jeffrey Orridge to Board of Directors
TORONTO , Oct. 20, 2023 /CNW/ - Think Research Corporation (TSXV: THNK) (" TRC " or the " Company "), a company focused on transforming healthcare through digital health software solutions, announced today that it has appointed Jeffrey Orridge to its Board of Directors. Mr. Orridge is a proven leader with a background in Software-as-a-Service ("SaaS"), Artificial Intelligence ("AI"), brand marketing, and government.
Sachin Aggarwal , Chief Executive Officer of Think Research said "We are excited to appoint Jeffrey to the Think Board of Directors because he brings a skill set and experience that aligns well with the strategic direction that we are currently pursuing."
Jeffrey Orridge commented "I am very pleased to be joining the Board of Directors of Think Research. I believe that my skills and experience in SaaS, AI, marketing and government will offer value-added guidance to Sachin and the rest of the Management team as it delivers essential data and solutions to help constrained healthcare systems globally provide the care that everyone needs."
Mr. Orridge is currently the Chief Executive Officer of TVO Media Education Group, was the past Chair of Tiidal Gaming prior to its public listing, and also Commissioner of the CFL among other senior positions.
Mr. Orridge joins an esteemed Think Research Board of Directors including, Dr. Eric Hoskins , Partner, Maverix Private Equity; Chair, Federal Advisory Council on the Implementation of National Pharmacare; former Minister of Health and Long Term Care, Ontario, Kirstine Stewart , author of bestselling leadership book Our Turn and Non-Executive Officer of Blink49Studios Inc.; Cindy Gray , Managing Director, Chief Executive Officer and the founder of 5 Quarters Investor Relations, Inc. a Calgary -based consulting firm; Barry Reiter , Partner Bennett Jones LLP; Richard Wells , Chief Financial Officer of Waterton Global Resource Management, Inc. and Partner, Finance at Kinterra Capital Corp.; Abe Schwartz , President of Schwartz Technologies Corporation; and Sachin Aggarwal , CEO of Think Research since 2010.
Mr. Orridge's appointment is subject to the requisite clearing of his Personal Information Form in accordance with the rules of the TSX Venture Exchange.
Think Research Corporation is an industry leader in delivering knowledge-based digital health software solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process and standardization of care to facilitate better health care outcomes. The Company gathers, develops, and delivers knowledge-based solutions globally to customers including enterprise clients, hospitals, health regions, healthcare professionals, and / or governments. The Company has gathered a significant amount of data by building its repository of knowledge through its network and group of companies.
Think licenses its solutions to over 14,200 facilities for over 320,000 primary care, acute care, and long-term care doctors, nurses and pharmacists that rely on the content and data provided by Think to support their practices. Millions of patients and residents annually receive better care due to the essential data that Think produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and clinical trial data via its BioPharma Services subsidiary. BioPharma Services is a leading provider of bioequivalence and Phase 1 clinical research services to pharmaceutical companies globally. Think's other services include a network of digital-first primary care clinics and medical clinics that provide elective surgery. Visit www.thinkresearch.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information: https://www.thinkresearch.com/ca/investors/
Sign Up To Get Daily Life Science Stock News
Stock quote, featured stock.
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
Market Moving News
Amneal Pharmaceuticals Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension...
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients...
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a...
AstraZeneca: FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Johnson & Johnson to Acquire Shockwave Medical
Gilead Sciences Completes $4.3 Billion Acquisition of CymaBay Therapeutics
End of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB
- Privacy Policy
- FDA Catalyst Calendar
- Insider Transactions
- Life Science Stock Lists
- All Life Science Stocks
- All Life Science Stock News
- Clinical Trial News
- Company FDA Updates
- Mergers & Acquisitions
- Search News & Events
- Top Stocks in 2024
- Artificial Intelligence
- Obesity Drugs
- Psychedelic Stocks
- Follow Us On Twitter
- Advertise Your Company
English (USA)
English (UK)
English (Canada)
English (India)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Français (France)
Français (Suisse)
Nederlands (Nederland)
Nederlands (België)
- Top Capitalization
- United States
- North America
- Middle East
- Sector Research
- Earnings Calendar
- Equities Analysis
- Most popular
- NIPPON ACTIVE VALUE FUND PLC
- CECONOMY AG
- TESLA, INC.
- GEA GROUP AG
- NETFLIX, INC.
- AMD (ADVANCED MICRO DEVICES)
- Index Analysis
- Indexes News
- EURO STOXX 50
- Currency Cross Rate
- Currency Converter
- Forex Analysis
- Currencies News
- Precious metals
- Agriculture
- Industrial Metals
- Livestock and Cattle
- CRUDE OIL (WTI)
- CRUDE OIL (BRENT)
- Developed Nations
- Emerging Countries
- South America
- Analyst Reco.
- Capital Markets Transactions
- New Contracts
- Profit Warnings
- Appointments
- Press Releases
- Security Transactions
- Earnings reports
- New markets
- New products
- Corporate strategies
- Legal risks
- Share buybacks
- Mergers and acquisitions
- Call Transcripts
- Currency / Forex
- Commodities
- Cryptocurrencies
- Interest Rates
- Asset Management
- Climate and ESG
- Cybersecurity
- Geopolitics
- Central Banks
- Private Equity
- Business Leaders
- All our articles
- Most Read News
- All Analysis
- Satirical Cartoon
- Today's Editorial
- Crypto Recap
- Behind the numbers
- All our investments
- Asia, Pacific
- Virtual Portfolios
- USA Portfolio
- European Portfolio
- Asian Portfolio
- My previous session
- My most visited
- Trend-Following Stocks
- Undervalued stocks
- Quality stocks
- Momentum stocks
- Warren Buffett
- Strategic Metals
- Unusual volumes
- New Historical Highs
- New Historical Lows
- Top Fundamentals
- Sales growth
- Earnings Growth
- Profitability
- Rankings Valuation
- Enterprise value
- Top Consensus
- Analyst Opinion
- Target price
- Estimates Revisions
- Top ranking ESG
- Environment
- Visibility Ranking
- Stock Screener Home
- Place your bets
- The food of tomorrow
- E-Commerce & Logistics
- Oversold stocks
- Overbought stocks
- Close to resistance
- Close to support
- Accumulation Phases
- Most volatile stocks
- Top Investor Rating
- Top Trading Rating
- Top Dividends
- Low valuations
- All my stocks
- Stock Screener
- Stock Screener PRO
- Portfolio Creator
- Event Screener
- Dynamic Chart
- Economic Calendar
- ProRealTime Trading
- Our subscriptions
- Our Stock Picks
- Thematic Investment Lists
Think Research Corporation
Ca88410j1075.
- Think Research Corporation Appoints Jeffrey Orridge to Its Board of Directors
Think Research Corporation announced that it has appointed Jeffrey Orridge to its Board of Directors. Mr. Orridge is a proven leader with a background in Software-as-a-Service ("SaaS"), Artificial Intelligence ("AI"), brand marketing, and government. Mr. Orridge is currently the Chief Executive Officer of TVO Media Education Group, was the past Chair of Tiidal Gaming prior to its public listing, and also Commissioner of the CFL among other senior positions.
Mr. Orridge joins an esteemed Think Research Board of Directors including, Dr. Eric Hoskins, Partner, Maverix Private Equity; Chair, Federal Advisory Council on the Implementation of National Pharmacare; former Minister of Health and Long Term Care, Ontario,Kirstine Stewart, author of bestselling leadership book Our Turn and Non-Executive Officer of Blink49Studios Inc.; Cindy Gray, Managing Director, Chief Executive Officer and the founder of 5 Quarters Investor Relations Inc. a Calgary-based consulting firm; Barry Reiter, Partner Bennett Jones LLP; Richard Wells, Chief Financial Officer of Waterton Global Resource Management Inc. and Partner, Finance at Kinterra Capital Corp.; Abe Schwartz, President of Schwartz Technologies Corporation; and Sachin Aggarwal, CEO of Think Research since 2010. Mr. Orridge's appointment is subject to the requisite clearing of his Personal Information Form in accordance with the rules of the TSX Venture Exchange.
Latest news about Think Research Corporation
Chart think research corporation.
Company Profile
Income statement evolution, ratings for think research corporation, analysts' consensus, eps revisions, quarterly earnings - rate of surprise, sector other software.
- Stock Market
- News Think Research Corporation
Think Research Corporation
TSXV:THNK Stock Report
Market Cap: CA$24.6m
Think Research Management
Management criteria checks 2/4.
Think Research's CEO is Sachin Aggarwal, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is CA$700.00K, comprised of 57.1% salary and 42.9% bonuses, including company stock and options. directly owns 3.82% of the company’s shares, worth CA$937.46K. The average tenure of the management team and the board of directors is 2.3 years and 3.3 years respectively.
Key information
Sachin Aggarwal
Chief executive officer
Total compensation
Recent management updates
Think research corporation, annual general meeting, apr 04, 2024, insufficient new directors, think research corporation appoints jeffrey orridge to its board of directors, think research corporation announces bridge loan, think research corporation, annual general meeting, aug 11, 2023, high number of new directors, recent updates, beedie capital entered into an arrangement agreement to acquire remaining 96.27551% stake in think research corporation (tsxv : thnk) from shareholders for cad 25.58 million., is think research (cve:thnk) using debt in a risky way.
New major risk - Market cap size
New major risk - share price stability, little excitement around think research corporation's (cve:thnk) revenues as shares take 28% pounding.
New minor risk - Share price stability
Third quarter 2023 earnings: eps exceeds analyst expectations while revenues lag behind, think research corporation to report q3, 2023 results on nov 27, 2023, why investors shouldn't be surprised by think research corporation's (cve:thnk) 26% share price plunge.
Price target decreased by 14% to CA$0.73
Second quarter 2023 earnings: eps exceeds analyst expectations, think research corporation to report q2, 2023 results on aug 29, 2023, first quarter 2023 earnings released: ca$0.047 loss per share (vs ca$0.11 loss in 1q 2022), think research corporation to report q1, 2023 results on may 29, 2023, consensus eps estimates fall by 17%, full year 2022 earnings: eps misses analyst expectations, think research corporation (cve:thnk) shares could be 48% below their intrinsic value estimate.
Analysts Have Been Trimming Their Think Research Corporation (CVE:THNK) Price Target After Its Latest Report
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind
Think research corporation to report q3, 2022 results on nov 28, 2022, think research appoints john hayes as permanent chief financial officer, consensus revenue estimates fall by 11%, price target decreased to ca$1.25, second quarter 2022 earnings: eps and revenues miss analyst expectations, think research corporation to report q2, 2022 results on aug 29, 2022, consensus forecasts updated, think research corporation, annual general meeting, aug 02, 2022, think research corporation to report q1, 2022 results on may 30, 2022, now 26% undervalued after recent price drop, now 24% undervalued after recent price drop, full year 2021 earnings: eps and revenues miss analyst expectations, think research corporation announced that it expects to receive cad 25 million in funding from beedie capital, price target decreased to ca$3.08, think research corporation announces executive changes, think research launches electronic data capture system for its clinical research phase 1 business, bio pharma services inc, think research corporation attests to vendor verification for virtual care in ontario, ceo & director recently sold ca$86k worth of stock, chief operating officer riyaz lalani has left the company, think research corporation (tsxv:thnk) completed the acquisition of biopharma services inc. from mahy investments ltd., moske investments ltd., n & m medical enterprises inc., ola kassim medicine professional corporation and kashima international inc. for cad 43.3 million., consensus revenue estimates increase to ca$45.4m, think research corporation (tsxv:thnk) entered into a definitive agreement to acquire biopharma services inc. for cad 44.6 million., think research corporation sees 140% year-over-year growth for eforms electronic data capture software in u.s. post-acute care market, think research corporation provides earnings guidance for the first quarter ended march 31, 2021, analysts expect breakeven for think research corporation (cve:thnk) before long.
Think Research Partners with Carerx to Deliver Virtualcare Telemedicine Software in Retirement Homes Across Canada
Carerx corporation and think research corporation announces their canada-wide partnership to deliver virtual healthcare to seniors, full year 2020 earnings released: ca$0.40 loss per share (vs ca$0.59 loss in fy 2019), think research corporation (tsxv:thnk) completed the acquisition of clinic 360 for cad 5.5 million., think research corporation (tsxv:thnk) acquired airmed trials inc. for cad 0.75 million., think research corporation (tsxv:thnk) entered into a share purchase agreement to acquire mdbriefcase inc. from pcp gp, l.p. ,jason flowerday and others for cad 24.9 million, think research announces appointment of dr. eric hoskins to board of directors, think research corporation (tsxv:thnk) agreed to acquire clinic 360 for cad 5.8 million., ceo compensation analysis.
Compensation vs Market : Sachin's total compensation ($USD507.03K) is above average for companies of similar size in the Canadian market ($USD173.69K).
Compensation vs Earnings : Sachin's compensation has increased whilst the company is unprofitable.
Compensation
Mr. Sachin Aggarwal has been Chief Executive Officer at Think Research Corporation since 2014 and serves as its Director since September 2010. He served as Chief Operating Officer at Think Research Corpora ... Show more
Leadership Team
Average tenure.
Experienced Management : THNK's management team is considered experienced (2.3 years average tenure).
Board Members
Average age.
Experienced Board : THNK's board of directors are considered experienced (3.3 years average tenure).
- SUGGESTED TOPICS
- The Magazine
- Newsletters
- Managing Yourself
- Managing Teams
- Work-life Balance
- The Big Idea
- Data & Visuals
- Reading Lists
- Case Selections
- HBR Learning
- Topic Feeds
- Account Settings
- Email Preferences
Research: Boards Still Have an ESG Expertise Gap — But They’re Improving
- Tensie Whelan
Over the last five years, the percentage of Fortune 100 board members possessing relevant credentials rose from 29% to 43%.
The role of U.S. public boards in managing environmental, social, and governance (ESG) issues has significantly evolved over the past five years. Initially, boards were largely unprepared to handle materially financial ESG topics, lacking the necessary background and credentials. However, recent developments show a positive shift, with the percentage of Fortune 100 board members possessing relevant ESG credentials rising from 29% to 43%. This increase is primarily in environmental and governance credentials, while social credentials have seen less growth. Despite this progress, major gaps remain, particularly in climate change and worker welfare expertise. Notably, the creation of dedicated ESG/sustainability committees has surged, promoting better oversight of sustainability issues. This shift is crucial as companies increasingly face both regulatory pressures and strategic opportunities in transitioning to a low carbon economy.
Knowing the right questions to ask management on material environmental, social, and governance issues has become an important part of a board’s role. Five years ago, our research at NYU Stern Center for Sustainable Business found U.S. public boards were not fit for this purpose — very few had the background and credentials necessary to provide oversight of ESG topics such as climate, employee welfare, financial hygiene, and cybersecurity. Today, we find that while boards are still woefully underprepared in certain areas, there has been some important progress .
- TW Tensie Whelan is a clinical professor of business and society and the director of the NYU Stern Center for Sustainable Business, and she sits on the advisory boards of Arabesque and Inherent Group.
Partner Center
Ideas + Action for a Better City
Welcome 2024–25 SPUR Board Directors and City Advisory Board Members
By lydia tan, spur board chair, and jean fraser, san francisco city advisory board member.
This month, 12 years after SPUR's regional expansion, the organization ushered in a new board governance structure. Our smaller, 30-member Board of Directors will provide fiduciary and strategic leadership to the organization in partnership with our three City Advisory Boards, which will support SPUR’s local research and advocacy efforts.
These new appointees bring extensive knowledge in planning, housing, transportation, good government, economy, and sustainability and resilience. We look forward to their leadership as we continue our work to make the Bay Area a place where everyone can thrive. For more details about our Board of Directors and City Advisory Board members, please visit spur.org/about/board .
SPUR Board Executive Committee
Lydia Tan, Chair Principal, Tan Consulting
Ariane Coleman Hogan, Vice Chair Director for Local Government Affairs, Genentech
Lindsay Baker, Secretary CEO, International Living Future Institute
Cynthia Wong, Treasurer Director of Operations, Education Initiative, Chan Zuckerberg Initiative
Jaye Bailey Chief of Staff, VTA
Daniel Cedeño Chief of Staff, Principal Regional Operations Specialist, PG&E
David Friedman Retired
Ed Harrington Retired: Former Controller, City and County of San Francisco (1991-2008), former General Manager San Francisco Public Utilities Commission (2008-2012)
Carl Shannon Senior Managing Director, Tishman Speyer
SPUR Board Directors
Jay Bradshaw Executive Officer, Nor Cal Carpenters Union
Shiyama Clunie Public Affairs Director, Golden Gate Service Area, Kaiser Permanente
Sam Cobbs CEO, Tipping Point Community
Lynette Dias President, Principal, Urban Planning Partners
John Diffenderfer President, Aedis Architects
Oz Erickson Principal, Emerald Fund
Don Falk Independent Affordable Housing Consultant
Sally Ann Flood West Region Real Estate Audit Leader, Deloitte
David Hart President, Steinberg Hart
Brian Jencek Senior Principal, Global Director for Urban Planning & Landscape Architecture, HOK
Dawn Kamalanathan Chief Facilities Officer, San Francisco Unified School District
Hao Ko Managing Director, Principal, Gensler
Gregg Miller Partner, Real Estate and Land Use, Coblentz, Patch, Duffy, & Bass, LLP
David Nieh Partner, AGI Avant Group
Shannon Peloquin Partner, San Francisco, McKinsey & Company, Inc.
Rebecca Prozan Senior Manager, Government Affairs and Public Policy, Google
Shakirah Simley Executive Director, Booker T. Washington Community Service Center
Joe Speicher Chief Sustainability Officer, Autodesk
Ari Takata-Vasquez Executive Director, Oakland Indie Alliance
Ben Tripousis Associate Vice President and Senior Program Manager, HNTB
Molly Turner Lecturer, University of California, Berkeley
San Francisco City Advisory Board Members
Hao Ko, Chair Managing Director, Principal, Gensler
Genevieve Cadwalader, Vice Chair Vice President, Investment Officer, Prologis
Ana Luisa Aldana Public Sector Client Account Director, DEIB+ Lead, Accenture
Chris Brown Senior Vice President, U.S. Business Partnerships & Policy, Citi
Kim-Mai Cutler Partner, Initialized Capital
Kelly Dearman Executive Director, Disability and Aging Services, San Francisco Human Services Agency
Sarah Dennis Phillips Executive Director, San Francisco Office of Economic and Workforce Development
Tamsen Drew Chief of Staff, Office of the General Counsel, Salesforce
Stephen Engblom Faculty, College of Environmental Design, University of California, Berkeley
Tyra Fennell Director of Community Relations and Commissions, San Francisco Mayor's Office of Housing and Community Development
Jean Fraser Chief Executive Officer, The Presidio Trust
Dorka Keehn Principal, Keehn on Art
Guillermo Rodriguez California State Director, The Trust for Public Land
Jack Sylvan Founder and Principal, SDG, LLC
Kate White Associate Principal for Planning and Policy, Arup
Lauren Wilson Senior Manager, Government Affairs, New Markets West, Cruise
San José City Advisory Board Members
Ben Tripousis, Chair Associate Vice President and Senior Program Manager, HNTB
Kathy Duong, Vice Chair Manager, Public Policy, Amazon
Anil Babbar Senior Vice President, Public & Government Affairs, California Apartment Association
Gary Dillabough Managing Partner, Navitas Capital
Shelley Doran Senior Vice President, Webcor
Rosalynn Hughey Deputy City Manager, City of San José
Ria Hutabarat Lo Transportation Manager, City of Mountain View
Christine Laing Studio Director, Principal, Gensler
Jim Lightbody Principal, Lightbody Consulting
Camille Llanes-Fontanilla Vice President, Silicon Valley Programs, Sobrato Family Foundation
Barbara Marshman Retired
Chris Neale Executive Vice President, The Core Companies
Kristina Raspe Vice President, Global Real Estate and Facilities, Apple
James Reber Executive Director, San José Parks Foundation
Karla Rodriguez Lomax Public Affairs Director, South Bay and Central Coast, Kaiser Permanente
Jasneet Sharma Director, Office of Sustainability, County of Santa Clara
Kelly Snider Professor in the Department of Urban and Regional Planning, Director of the Certificate in Real Estate Development Program, San José State University
Leah Toeniskoetter President & CEO, San José Chamber of Commerce
Geri Wong Senior Managing Director, Newmark San José
Oakland City Advisory Board Members
Lynette Dias, Co-Chair President, Principal, Urban Planning Partners
Molly Turner, Co-Chair Lecturer, University of California, Berkeley
Carolyn Johnson Chief Executive Officer, Black Cultural Zone
Andrea Lowe President & CEO, Lowe Consulting Group, Inc.
Jay Murphy Capital Projects Team Manager, National Facility Services Support Services Administrator, Kaiser Permanente
Chek Tang President, Studio T Square
Amy Tharpe Director of Social Responsibility, Port of Oakland
- Skip to main content
- Keyboard shortcuts for audio player
Consider This from NPR
- LISTEN & FOLLOW
- Apple Podcasts
- Google Podcasts
- Amazon Music
Your support helps make our show possible and unlocks access to our sponsor-free feed.
Is this fictitious civil war closer to reality than we think?
You're reading the Consider This newsletter, which unpacks one major news story each day. Subscribe here to get it delivered to your inbox, and listen to more from the Consider This podcast .
(L-R) Kirsten Dunst, Cailee Spaeny Murray Close/A24 hide caption
(L-R) Kirsten Dunst, Cailee Spaeny
1. A civil war for the silver screen
Civil War, the new A24 film from British director Alex Garland, imagines a scenario that might not seem so far-fetched to some; a contemporary civil war breaking out in the United States.
In this world, the U.S. has split into various factions. The president, played by Nick Offerman – has given himself a third term, and he's hoping to fend off an assault from one of the more powerful groups.
In what might seem like the most unbelievable narrative twist, California and Texas form an alliance to become the "Western Forces" and fight against Offerman's regime. Sure, I guess!
Some independent candidates start their own political parties to ease ballot access
2. how far are we from reality.
NPR movie critic Bob Mondello says the movie doesn't do a lot of explaining to help us understand how the U.S. got to this moment. But he says that makes it stronger.
"What became much more interesting in the moment was what it looks like to transpose things that we've always associated with other countries – the bombed out helicopters and things like that – to place that in a J.C. Penney parking lot."
And while the film has taken heat for little mention of politics, the question of an actual civil war has everything to do with it.
Polling has shown a significant minority thinks a civil war is at least somewhat likely in the next 10 years. So what do the experts say?
Movie Reviews
'civil war' is a doomsday thought experiment — that could have used more thinking, 3. division in the u.s..
Amy Cooter is a director of research at the Center on Terrorism, Extremism, and Counterterrorism at the Middlebury Institute of International Studies. Her work has led her to the question that Garland's movie has put in the minds of both moviegoers and political pundits: Could a second civil war really happen here?
Cooter wants to make one thing clear: "I don't think that civil war is imminent, but I think there are some people who wish we would have one, and wish that they could be effectively culture soldiers to re-enact a civil order that they see as better for them and their families."
In her studies of militias and political extremists, Cooter has observed a movement of groups similar to those who joined in on the January 6th riots who feel disconnected from the current political moment, or perhaps want to return to a previous version of society, that they feel served them better.
And while Cooter doesn't think a civil war will be happening anytime soon, she does say this:
"I think we are at a moment of extreme political division that may get worse before it gets better."
This episode was produced by Marc Rivers. It was edited by Jeanette Woods, Jonaki Mehta and Courtney Dorning. Our executive producer is Sami Yenigun.
- far-right extremism
- political divide
Become a member today, It's free!
Remember me
Send my password
Think research enters into definitive agreement to be acquired by beedie capital.
• Think Research Corporation shareholders to receive cash payment of $0.32 per Common Share, representing a 100% premium to the closing price of the Common Shares on February 15, 2024 and a 75% premium to the 30-day volume-weighted average trading price of the Common Shares • Special Committee and Board (excluding any interested directors) unanimously determined the Transaction is in the best interests of the Company, and the Board (excluding any interested directors) has recommended that shareholders vote in favour of the Transaction • Certain shareholders, including Chief Executive Officer, Sachin Aggarwal, to roll their equity ownership • Shareholders holding 48.21% of the Common Shares have agreed to support the Transaction • Think Research Corporation will continue to execute on its strategy of delivering knowledge-based digital health software solutions as a private company upon the completion of the Transaction
TORONTO, ON / ACCESSWIRE / February 16, 2024 / Think Research Corporation (TSXV:THNK) (" Think " or the " Company "), a company focused on transforming healthcare through digital health software solutions, today announced that it has entered into an arrangement agreement (the " Arrangement Agreement ") with Beedie Investments Ltd. (" Beedie Capital "), a multi-strategy direct investment platform managing alternative investments for one of the largest private companies in Western Canada, pursuant to which Beedie Capital will acquire all of the common shares in the capital of the Company (the " Shares "), other than those Shares owned by Beedie Capital and other shareholders comprised of certain directors and executive officers of the Company as well as other persons (such shareholders, collectively, the " Continuing Shareholders "), for cash consideration of $0.32 per Share (the " Consideration ") (collectively, the " Transaction "). The Consideration represents a 100% premium to the closing price of the Shares on the TSX Venture Exchange (the " TSXV ") on February 15, 2024, the last trading day immediately prior to the announcement of the Transaction, and a 75% premium to the 30-day volume-weighted average price (" VWAP ") of the Shares on the TSXV for the period ended February 15, 2024. As of the date hereof, the Continuing Shareholders, collectively, beneficially own or control an aggregate of 21,706,567 Shares (representing approximately 27.4% of the issued and outstanding Shares on a non-diluted basis).
"The Think team is pleased that Beedie Capital has demonstrated its confidence in the Company through this Transaction, the Consideration of which reflects a strong endorsement of the Company's value. Beedie Capital has a deep understanding of our business and we look forward to working with them to continue executing on our plan to accelerate growth and provide digital solutions to clinicians worldwide," said Think Research's Chief Executive Officer, Sachin Aggarwal. "In addition, the Transaction eliminates the financial and administrative burden of continuing as a reporting issuer in what is already a challenging market environment."
Richard Wells, an independent director of the Think board of directors (the " Board ") and Chair of the Special Committee, said, "After a comprehensive process and careful deliberation, supported by external professional advisors, the Special Committee considers that the Transaction represents the best available path forward for the Company, its shareholders, lenders, employees and other stakeholders. This Transaction provides a cash premium and immediate liquidity to holders of Shares and the Board is unanimous in its belief that this Transaction is in the best interests of all Think shareholders."
Special Committee and Board Recommendations
The Arrangement Agreement was approved unanimously by the Board (with any interested director abstaining from voting due to his or her participation in the Transaction as a Continuing Shareholder), after taking into account, among other things, the unanimous recommendation of a special committee (the " Special Committee ") of the Board comprised of Richard Wells, Cindy Gray and Jeffrey Orridge, each an independent director of the Company. The Special Committee and the Board (with the abstention of any interested directors) determined that the Transaction is in the best interests of the Company and the Board recommends that holders of Shares (other than Beedie Capital and the Continuing Shareholders) vote in favour of the Transaction at the Meeting (as defined below).
In making its determination to unanimously recommend approval of the Transaction to the Board, and in the Board's determination to approve the Transaction, the Special Committee and the Board considered the following factors, among other things:
• Compelling Value and Immediate Liquidity - the all-cash Consideration provides shareholders with immediate value and is of particular benefit given the limited trading volume, the financial challenges facing the Company and the lack of liquidity in the Shares. The Consideration represents a 100% premium to the closing price of the Shares on the TSXV on February 15, 2024, the last trading day immediately prior to the announcement of the Transaction, and a 75% premium to the 30-day VWAP of the Shares on the TSXV for the period ended February 15, 2024; • Fairness Opinion - the Special Committee received an oral fairness opinion from Canaccord Genuity Corp. ("Canaccord"), which opinion concluded that, based upon and subject to the assumptions made, procedures followed, matters considered, limitations and qualifications set out therein, the Consideration to be received by the shareholders (other than Beedie Capital and the Continuing Shareholders) pursuant to the Transaction is fair, from a financial point of view, to the shareholders. A written copy of the fairness opinion will be included in the materials sent to shareholders in connection with the Meeting; • Go-Shop Provision - the Arrangement Agreement includes a go-shop provision, during which time the Company, with the assistance of Canaccord, will be permitted to actively solicit, evaluate and enter into negotiations with respect to a potential Superior Proposal (as defined in the Arrangement Agreement) for a 30-day period, as more particularly described below; • Support for the Transaction - each of the Continuing Shareholders and certain other shareholders, directors that hold Shares and certain officers of the Company has entered into a voting support agreement, pursuant to which they have agreed to, among other things, vote their Shares, which represent approximately 48.21% of all of the Shares, in favour of the Transaction at the Meeting; • Arrangement Agreement and "Fiduciary Out" - the Arrangement Agreement is the result of a comprehensive negotiation process that was supervised by the Special Committee, as advised by independent and highly qualified legal and financial advisors, and resulted in terms and conditions that are reasonable in the judgment of the Special Committee and the Board, including a customary "fiduciary out" that will enable the Company to enter into a Superior Proposal in certain circumstances; • Break Fee - the break fee payable by the Company equal to $1,065,943 is reasonable in the circumstances and only payable in customary and limited circumstances; and • Minority Vote and Court Approval - the Transaction must be approved not only by at least two-thirds (66?%) of the votes cast by shareholders, but also by a majority of the minority in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), and by the Ontario Superior Court of Justice (Commercial List).
Transaction Details
Pursuant to the terms of the Arrangement Agreement, Beedie Capital will acquire all of the Shares, other than those Shares owned by Beedie Capital and the Continuing Shareholders, for a purchase price of $0.32 per Share, payable in cash. The Transaction is to be effected by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) and is expected to close in the second quarter of 2024, subject to shareholder, court and regulatory approvals and other closing conditions customary to transactions of this nature. Completion of the Transaction is not subject to any financing condition.
The Arrangement Agreement includes a go-shop period extending until March 16, 2024 (the " Go-Shop Period "), during which time the Company, with the assistance of Canaccord, will, subject to the requirements and limitations set forth in the Arrangement Agreement, be permitted to actively solicit, evaluate and enter into negotiations with third parties that express an interest in acquiring the Company with a view to obtaining a potential Superior Proposal. Following the expiry of the Go-Shop Period, the Company will be subject to customary non-solicitation covenants with customary "fiduciary out" provisions that entitle the Special Committee and the Board to consider and, subject to certain conditions, accept a Superior Proposal if Beedie Capital does not match such Superior Proposal. If the Arrangement Agreement is terminated under certain circumstances, including circumstances in which the Company terminates the Arrangement Agreement to accept a Superior Proposal prior to approval of the Transaction by shareholders, a termination fee equal to $1,065,943 is payable by the Company to Beedie Capital. There can be no assurance that a Superior Proposal will be made as a result of the go-shop process or otherwise, and the Company does not intend to disclose developments with respect to the go-shop process or any interest received by third parties during the Go-Shop Period, unless and until the Special Committee and the Board make a determination requiring further disclosure.
A special meeting of holders of Shares to consider and, if deemed advisable, approve the Transaction (the " Meeting ") is expected to be held in early April 2024. In order to be approved by holders of Shares at the Meeting, the Transaction will require the approval of: (a) at least two-thirds (66 ?%) of the votes cast at the Meeting in person or by proxy by holders of Shares; and (b) a simple majority of the votes cast at the Meeting in person or by proxy by holders of Shares (other than Shares required to be excluded under MI 61-101 and applicable TSXV rules).
Additional details regarding the Transaction, the background to the Transaction, the reasons for the Board and Special Committee's recommendations of the Transaction, and how Company shareholders can participate in and vote at the Meeting, will be set out in the Company's management information circular and other proxy-related materials to be prepared, filed and sent to the Company's shareholders in connection with the Meeting. Copies of the Arrangement Agreement and the management information circular for the Meeting will be filed with Canadian securities regulators and will be made available on the SEDAR+ profile of the Company at www.sedarplus.ca . Shareholders of the Company are urged to read those and other relevant materials when they become available. Upon closing of the Arrangement, the Purchaser intends to cause the Shares to be delisted from the TSXV and will submit an application to cease to be a reporting issuer under applicable Canadian securities laws.
Voting Support Agreements
In connection with the Transaction, the Continuing Shareholders and certain other shareholders, and all directors who hold Shares and certain officers of the Company, who hold, in aggregate, 38,194,731 Shares (representing approximately 48.21% of the issued and outstanding Shares (on a non-diluted basis)), have entered into voting support agreements with Beedie Capital, providing for such shareholders to vote all Shares owned by them in favour of the Transaction.
Canaccord Genuity Corp. is acting as financial advisor to the Special Committee. Cassels Brock & Blackwell LLP is acting as independent legal advisor to the Special Committee. Stikeman Elliott LLP is acting as legal advisor to the Company.
Dentons Canada LLP is acting as legal advisor to Beedie Capital.
Early Warning Information
In connection with the Arrangement Agreement, in addition to the voting support agreement described above, Beedie Capital and the Continuing Shareholders have entered into a framework agreement dated as of the date hereof, which sets forth certain covenants and agreements between Beedie Capital and the Continuing Shareholders as it relates to the Transaction, the Shares held by the Continuing Shareholders and the relationship of such parties immediately following closing of the Transaction. It is intended that, immediately following the Transaction, the Company will make an application to cease to be a reporting issuer under Canadian securities law.
Both immediately before and immediately after the execution of the Arrangement Agreement, Beedie Capital held or exercised control or direction over (i) 2,934,900 Shares, representing approximately 3.7% of the issued and outstanding Shares (on a non-diluted basis), (ii) assuming the conversion in full of the aggregate principal amount outstanding under the non-revolving term convertible loan facility made available by Beedie Capital to the Company (the " Convertible Loan ") of $21 million using the applicable conversion price as of the respective dates of each advance under the Convertible Loan, an aggregate of 43,078,065 Shares, representing approximately 36.1% of the issued and outstanding Shares (on a partially-diluted basis), and (iii) assuming the conversion in full of the principal amounts outstanding under the Convertible Loan together with the remaining $4 million of subsequent advances thereunder at a conversion price of $0.20 per share, representing a 25% premium above the closing price of the Shares on the TSXVas of February 15, 2024, an aggregate of 63,039,057 Shares, representing approximately 45.25% of the issued and outstanding Shares (on a partially-diluted basis). Following the completion of the Transaction, Beedie Capital will own approximately 72.6% of the issued and outstanding Shares.
An early warning report will be filed by Beedie Capital in accordance with applicable securities laws and will be available on SEDAR+ at www.sedarplus.ca or may be obtained directly from Beedie Capital upon request at 604-436-7888. Beedie Capital's head office is located at Suite 900 - 1111 West Georgia St., Vancouver, BC, V6E 4M3.
Forward Looking Information
This press release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information may be identified by statements including words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could,", "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and the conditional.
Statements including forward-looking information may include, without limitation, statements regarding the rationale of the Special Committee and the Board for entering into the Arrangement Agreement, the expected benefits of the Transaction, the timing of various steps to be completed in connection with the Transaction, and other statements that are not material facts. Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to, that the parties will receive, in a timely manner and on satisfactory terms, the necessary court, shareholder and regulatory approvals, and that the parties will otherwise be able to satisfy, in a timely manner, the other conditions to the closing of the Transaction. The Company considers these assumptions to be reasonable in the circumstances. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. By its nature, forward-looking information involves known and unknown risks, uncertainties, changes in circumstances and other factors that are difficult to predict and many of which are outside of the Company's control which may cause actual results to differ materially from the any future or potential results expressed or implied by such forward-looking information. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, (i) the possibility that the Transaction will not be completed on the terms and conditions, or on the timing, currently contemplated, and that it may not be completed at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, required shareholder, regulatory and court approvals and other conditions of closing necessary to complete the Transaction or for other reasons; (ii) the possibility of adverse reactions or changes in business resulting from the announcement or completion of the Transaction; (iii) risks relating to the Company's ability to retain and attract key personnel during the interim period; (iv) the possibility of litigation relating to the Transaction; (v) the potential of a third party making a Superior Proposal; (v) risks related to diverting management's attention from the Company's ongoing business operations; and (vi) other risks inherent to the business carried out by the Company and factors beyond its control which could have a material adverse effect on the Company or its ability to complete the Transaction. The Company has assumed that the risk factors referred to above will not cause such forward-looking statements and information to differ materially from actual results or events. The reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.
Other than as specifically required by applicable Canadian law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, whether as a result of new information, future events or results, or otherwise.
About Think Research Corporation
Think Research Corporation is an industry leader in delivering knowledge-based digital health software solutions. The Company's focused mission is to organize the world's health knowledge so everyone gets the best care. Its evidence-based healthcare technology solutions support the clinical decision-making process and standardization of care to facilitate better health care outcomes. The Company gathers, develops, and delivers knowledge-based solutions globally to customers including enterprise clients, hospitals, health regions, healthcare professionals, and / or governments. The Company has gathered a significant amount of data by building its repository of knowledge through its network and group of companies.
The Company licenses its solutions to over 14,200 facilities for over 320,000 primary care, acute care, and long-term care doctors, nurses and pharmacists that rely on the content and data provided by the Company to support their practices. Millions of patients and residents annually receive better care due to the essential data that the Company produces, manages and delivers.
In addition, the Company collects and manages pharmaceutical and clinical trial data via its BioPharma Services subsidiary. BioPharma Services is a leading provider of bioequivalence and Phase 1 clinical research services to pharmaceutical companies globally. The Company's other services include a network of digital-first primary care clinics and medical clinics that provide elective surgery. Visit www.thinkresearch.com for more details.
About Beedie Capital
Beedie Capital is a multi-strategy direct investment platform that manages the alternative investments for Beedie, one of the largest private companies in Western Canada. It deploys capital using a flexible, evergreen mandate, and applies a highly agnostic approach to the duration, structure and size of its investments. Beedie Capital combines the strategic capabilities of an institutional investment platform with the flexibility and entrepreneurial mindset of a privately owned business. Beedie Capital invests in any sector, with a core focus on Technology, Tech-enabled Services, and Metals and Mining, and seeks to grow its invested capital alongside the enterprise value of its investments. For further information on Beedie Capital, please visit www.beediecapital.com .
For further information, please contact:
Mark Sakamoto Executive Vice President Think Research Corporation Direct: 416-388-7119 [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Think Research
Related News
@ the bell: markets deeply divided amid middle east flareup, @ the bell: tsx keeps it just above the flatline, @ the bell: tsx sees first positive day in a week, featured news links, positive pea for uranium-vanadium deposit after-tax npv 8%: $227.7 million with irr: 38.9%, fokus mining welcomes luc gervais to its board of directors, the increasing investments by the defense and military sectors is driving the demand for helium.
Get the latest news and updates from Stockhouse on social media
Follow STOCKHOUSE Today
More From Forbes
Rethinking emerging risks for 2024.
- Share to Facebook
- Share to Twitter
- Share to Linkedin
New research reveals the top business risks reported by corporate directors and officers globally ... [+] for 2024.
New research reveals the top business risks reported by corporate directors and officers globally for 2024, with the notable move of health and safety to the number-one spot from number five last year. Effective leaders adopt an enterprise-wide approach to analyzing emerging risks and creating optimal risk financing programs, asking key questions during their analysis.
The 2024 Global Directors and Officers Survey Report by WTW identifies the following top seven risks across more than 50 countries:
1. Health and safety
2. Cyber attack
3. Data loss
4. Regulatory breach
5. Systems and controls
6. Bribery and corruption
Apple Watch Series 9 Hits All-Time Low Special Offer Price
Israel conducts limited strikes targeting iran report says, the first unintended consequence of ai and it s huge.
7. Breach of sanctions
In addition to health and safety emerging as the top risk, new entrants on the list include systems and controls, and breach of sanctions, reflecting heightened geopolitical tensions and the increasing complexity of corporate governance.
Rankings vary by region. For example, climate change remains a top seven risk in Asia, Australasia and the Middle East, but not in other regions. Breach of human rights is the number two risk in Africa and a top seven risk in Asia. Civil litigation is a top seven risk in North America and Latin America. Board structure is a top seven risk is Asia. AI and machine learning is a top seven risk in the Middle East. Supplier business practices are a top seven risk in Africa.
With thanks to WTW’s Louise Pennington and Erin Boulware in a recent article in Business Insurance, effective leaders take the following actions to manage and mitigate risks:
1. Take a holistic approach to risk management and dynamic decision making: Today, effective boards and business leaders consider risks ranging from artificial intelligence, climate change and cyber, to geopolitical developments and societal shifts in labor. These leaders understand that traditional siloed risk approaches are insufficient in the current environment, which requires decision makers to adopt an enterprise-wide approach to analyzing emerging risks and creating optimal ways to finance risk exposure.
2. Agree on risk appetite for the organization: Effective leaders align risk management plans with organizational risk appetite and tolerance. Even within the same industry, companies may have vastly different abilities and appetites for financial volatility – one may prefer to retain risk, while another may elect to transfer risk whenever possible. The right route for a given organization depends on that organization’s financial strength and goals.
3. Adopt a portfolio approach to risk management and mitigation: Effective leaders use portfolio analysis when considering their organization’s total exposure across risks and when examining combinations of investment options to manage risk. Employing one language and framework across risk portfolios enables leaders to define the strategy that is right for their organization – in other words, the set of risk mitigation investments that delivers the needed risk protection for the least cost. For example, leaders can evaluate investments in areas such as supply chain resiliency, labor reskilling, or cyber security enhancements. The benefits will include minimizing cost or risk (or both), connecting organizational risk strategy with financial strategy, and enabling transparency and enhancing communication about risk across the organization.
4. Ask the right questions: Two of the most important questions effective leaders ask when considering novel risks are: What do these risks mean for our business? What are our options for managing these risks? Answering these questions often requires translating data through analytical models and algorithms. Additionally, the following questions serve as a framework for analysis to drive effective risk portfolio management and optimization:
· What unexpected, unfunded event would be material to the organization? Materiality differs for every organization and depends not only on size and strength, but also on the organization’s financial objectives.
· What events does the organization want to guard against? This question strives to identify types of losses that could exceed the organization’s risk tolerance.
· How do we guard against risks that are unknown or not on our screen? Experts often ask, “how can we avoid ‘failure of imagination’ in considering risks we have never experienced before?”
· What does the organization’s total risk picture look like? A thorough understanding of one’s total risk picture requires identification and quantification of risks. Even emerging and complex risks can be quantified, which represents an essential component of effective risk management.
· What can the organization do to mitigate risk? Another way to consider this question is, what investments can the organization make to reduce its risks?
· What risk financing solutions make the most sense for the organization? After considering the above questions, risk financing options become easier to answer as the protection gained from each investment in mitigation becomes more apparent.
Effective risk management in today’s dynamic and uncertain environment can be challenging to any board or senior management team. The most effective leaders employ an array of strategies to identify, assess, predict, be prepared for, and mitigate risks.
- Editorial Standards
- Reprints & Permissions
- International edition
- Australia edition
- Europe edition
Two sons of world’s richest man Bernard Arnault join him on board of LVMH
Pair also join two other siblings on board, further strengthening family’s control of French luxury goods company
Two sons of the world’s richest man, Bernard Arnault, have joined the board of LVMH after a shareholder vote, further cementing the family’s control of the French luxury goods company.
The pair joined their elder siblings on the board of directors of the company, which houses brands such as Dior and Louis Vuitton , meaning four of Bernard Arnault’s five children now sit on the board.
Alexandre, 31, is the executive vice-president of Tiffany, while Frédéric, 29, is the CEO of Swiss luxury watchmaker Tag Heuer.
The Forbes magazine currently lists Bernard Arnault, and his family, as the world’s richest person, with a fortune of $214bn (£172bn), ahead of Amazon founder Jeff Bezos and Elon Musk, who heads Tesla and X.
Each son got a vote of more than 93% at the shareholder meeting, with the results coming as no surprise.
The Arnault family group holds 48.6% of LVMH’s capital and 64.3% of the votes, a fact Arnault acknowledged shortly ahead of the proceedings.
“I’ve got the majority of votes, so …” he said.
Two other children from a previous marriage, Delphine , 49, and Antoine, 46, are already board members, but the youngest sibling, Jean, 26, still has to wait his turn.
“He has time, he’s young,” said the 75-year-old founder.
after newsletter promotion
LVMH (Moët Hennessy Louis Vuitton) also nominated Wei Sun Christianson to succeed Antonio Belloni, the group’s number two, who announced his departure at the end of March.
Christianson, who joins from American investment bank Morgan Stanley, is “a great expert on business in China”, said Arnault, stressing the value of the country’s market.
“The group has a strong presence in China, so it’s important to have precise views on what’s happening,” he added.
- Louis Vuitton
All billionaires under 30 have inherited their wealth, research finds
‘A historic step’: G20 discusses plans for global minimum tax on billionaires
Tax our wealth, super-rich tell politicians at Davos
What do the rich really think about a wealth tax? Not what you might imagine
India’s wealthy ‘fear London is worse than Delhi for muggings’
‘I’m creating the tax I would want to pay’: Austrian heiress Marlene Engelhorn on why she is giving away 90% of her wealth
Musk, Zuckerberg and most of rest of the world’s richest got richer in 2023
Luxury ski chalet with helipad and view of Matterhorn on sale for €24m
Harrods opens private members’ club in Shanghai costing £16,500 a year
Hermès billionaire plans to leave half of fortune to ex-gardener and cut ties with charity
Most viewed.
Board of Scientific and Clinical Directors
“The Board of Scientific Directors is charged to work in close collaboration with the NIH Clinical Directors to develop, review, and recommend policies affecting the intramural research programs of the NIH Institutes and Centers to the Deputy Director for Intramural Research (DDIR). Recommendations may require further approvals by higher-level authorities, such as the NIH Institute or Center (IC) Directors, or the Director, NIH.” [Charge to the Scientific Directors affirmed on March 24, 2022] . On July 27, 2023, the NIH Steering Committee of the NIH Director voted unanimously to approve the designation of the Board of Scientific Directors as the Board of Scientific and Clinical Directors.
Composition
The Board is co-chaired by the DDIR and an IC Director, and voting members of the Board include all NIH Scientific Directors and NIH Clinical Directors (or their official Deputy filed with OIR, or, on rare occasions, other designated alternate). The Executive Secretary is a Deputy or Associate Director, Office of Intramural Research (OIR). Other invited attendees include: the NIH Deputy Director; the NIH Deputy Director for Management; the Directors, Office of Human Resources (OHR), Office of Research Services (ORS), Office of Research Facilities (ORF), NIH Office of Equity, Diversity, and Inclusion (OEDI); a representative of the NIH Assembly of Scientists and staff members of the OIR.
Meetings are regularly scheduled from 9-11 a.m. on the first and third Wednesdays of each month currently fully virtual or in hybrid settings.
Scientific Directors (SDs) and Clinical Directors (CDs), including Acting SDs and CDs or designated alternates, are expected to attend all meetings.
Suggested agenda items should be brought to the attention of Dr. Charles R. Dearolf , Executive Secretary. Agendas are developed with input from the SD/CD Agenda Subcommittee , as well as the DDIR.
- NIH IRP Scientific Directors Roster
- NIH IRP Clinical Directors Roster
- Board of Scientific and Clinical Directors Subcommittees
- Orientation Manual for Scientific Directors
- Selected Responsibilities of a Scientific Director ( Management Controls Survey )
This page was last updated on Thursday, April 18, 2024
IMAGES
VIDEO
COMMENTS
Sachin has served on the Board of Directors for numerous community outreach programs, including Dixon Hall Neighbourhood Services and the People with AIDS Foundation. ... Kirsten is the Clinical Director on Think Research's Research and Development team and has been a registered nurse for nearly 30 years. Since joining Think Research, she has ...
Mr. Orridge joins an esteemed Think Research Board of Directors including, Dr. Eric Hoskins, Partner, Maverix Private Equity; Chair, Federal Advisory Council on the Implementation of National ...
TORONTO, Jan. 18, 2021 /CNW/ - Think Research Corporation (TSXV: THNK) announced today that it has appointed former Ontario Health Minister, Dr. Eric Hoskins, to its board of directors.Dr. Hoskins ...
Think Research Corporation (TSXV: THNK) ("TRC" or the "Company"), a company focused on transforming healthcare through digital health software solutions, announced today that it has appointed Jeffrey Orridge to its Board of Directors. Mr. Orridge is a proven leader with a background in Software-as-a-Service ("SaaS"), Artificial Intelligence ("AI"), brand marketing, and government.
Think Research Announces Appointment of New Director. 20 Oct, 2023, 07:00 ET. Oct. 20, 2023 /CNW/ - Think Research Corporation (TSXV: " or the " "), a company focused on transforming healthcare ...
Think Research Corporation (TSXV: THNK) ("TRC" or the "Company"), a company focused on transforming healthcare through digital health software solutions, announced today that it has appointed Jeffrey Orridge to its Board of Directors. Mr. Orridge is a proven leader with a background in Software-as-a-Service ("SaaS"), Artificial Intelligence ("AI"), brand marketing, and government.
Think CEO Sachin Aggarwal said, "We are delighted to have Dr. Hoskins become our Chair, increasing his engagement and contributions as a valued member of Think's Board of Directors. We thank Mr ...
TORONTO, Oct. 20, 2023 /CNW/ - Think Research Corporation (TSXV: THNK) ("TRC" or the "Company"), a company focused on transforming healthcare throu... Real-Time News, Market Data, and Stock Quotes for Life Science Stocks @ healthstockshub.com
Richard Wells, an independent director of the Think board of directors (the "Board") and Chair of the Special Committee, said, "After a comprehensive process and careful deliberation, supported by ...
(2023-10-20 | TSXV:THNK) Think Research Announces Appointment of New Director (2023-10-20 | TSXV:THNK) Think Research Announces Appointment of New Director. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our ...
Think Research has been backed in iGan Partners, Fidelity Investments Canada, Kayne Partners, Canaccord Genuity, NAVentures, Lumira Ventures and others. Sam Ifergan, President of iGan Partners, will join the new Think Research board of directors. photo credit : Think Research. News Release
Think Research Corporation announced that it has appointed Jeffrey Orridge to its Board of Directors. Mr. Orridge is a proven leader with a background in Software-as-a-Service ("SaaS"), Artificial Intelligence ("AI"), brand marketing, and government.
• Think Research Corporation shareholders to receive cash payment of $0.32 per Common Share, representing a 100% premium to the closing price of the Common Shares on February 15, 2024 and a 75% premium to the 30-day volume-weighted average trading price of the Common Shares ... Richard Wells, an independent director of the Think board of ...
Think Research's CEO is Sachin Aggarwal, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is CA$700.00K, comprised of 57.1% salary and 42.9% bonuses, including company stock and options. directly owns 3.82% of the company's shares, worth CA$952.58K. The average tenure of the management team and the board of ...
Think Research Management Team. Think Research has 15 executives. Think Research's current Chief Executive Officer is Sachin Aggarwal. You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together. Click Now.
TORONTO, ON / ACCESSWIRE / April 18, 2024 / Think Research Corporation (TSXV:THNK) ... Cassels Brock & Blackwell LLP acted as counsel to the Special Committee of Think's board of directors, ...
INTRODUCTION. The literature on board governance has major lacunae. It is prescriptive rather than descriptive, stronger on what authorities consider that boards should think and do than on what boards and their members actually think and do. It makes clear the major roles that a board must typically perform, namely control (Fama & Jensen, Reference Fama and Jensen 1983), stewardship (Westphal ...
The first step in synergistic board decision making, discovery, builds on this premise. Board members independently collect information relevant to the decision to bring multiple independent perspectives. By drawing on a wide range of information to guide their decision, these boards don't rely on data that may be steered by their CEO's agenda.
Over the last five years, the percentage of Fortune 100 board members possessing relevant credentials rose from 29% to 43%. The role of U.S. public boards in managing environmental, social, and ...
This month, 12 years after SPUR's regional expansion, the organization ushered in a new board governance structure. Our smaller, 30-member Board of Directors will provide fiduciary and strategic leadership to the organization in partnership with our three City Advisory Boards, which will support SPUR's local research and advocacy efforts. These new appointees bring extensive knowledge in ...
3. Division in the U.S. Amy Cooter is a director of research at the Center on Terrorism, Extremism, and Counterterrorism at the Middlebury Institute of International Studies.
V.THNK | February 16, 2024. • Think Research Corporation shareholders to receive cash payment of $0.32 per Common Share, representing a 100% premium to the closing price of the Common Shares on February 15, 2024 and a 75% premium to the 30-day volume-weighted average trading price of the Common Shares. • Special Committee and Board ...
The 2024 Global Directors and Officers Survey Report by WTW identifies the following top seven risks across more than 50 countries: 1. Health and safety. 2. Cyber attack. 3. Data loss. 4 ...
Thu 18 Apr 2024 13.38 EDT. Two sons of the world's richest man, Bernard Arnault, have joined the board of LVMH after a shareholder vote, further cementing the family's control on the French ...
JOHNSTON, R.I., USA, April 11, 2024 - Commercial property insurer FM Global today announced that FM Global President and Chief Executive Officer Malcolm C. Roberts has been appointed chair of the board by the company's board of directors. The appointment is effective immediately. Roberts succeeds Thomas A. Lawson, former president and CEO of FM Global, who has served as chair since 2018.
The Board is co-chaired by the DDIR and an IC Director, and voting members of the Board include all NIH Scientific Directors and NIH Clinical Directors (or their official Deputy filed with OIR, or, on rare occasions, other designated alternate). The Executive Secretary is a Deputy or Associate Director, Office of Intramural Research (OIR).